Last reviewed · How we verify
injection of NMBA
injection of NMBA is a Neuromuscular blocking agent Small molecule drug developed by Fondation Ophtalmologique Adolphe de Rothschild. It is currently FDA-approved for Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation.
NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.
NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction. Used for Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation.
At a glance
| Generic name | injection of NMBA |
|---|---|
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Drug class | Neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor at neuromuscular junction |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
NMBAs competitively or non-competitively inhibit acetylcholine receptors at the motor end plate, preventing muscle contraction. This is used during anesthesia and intubation to facilitate surgical access and mechanical ventilation. The effect is reversible and wears off as the drug is metabolized or cleared.
Approved indications
- Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation
Common side effects
- Residual neuromuscular blockade
- Histamine release (with certain agents)
- Anaphylaxis
- Malignant hyperthermia (in susceptible patients)
Key clinical trials
- Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient (PHASE3)
- A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982) (PHASE4)
- Assessment Study of the Effect of NMBA on Bowel Peristalsis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- injection of NMBA CI brief — competitive landscape report
- injection of NMBA updates RSS · CI watch RSS
- Fondation Ophtalmologique Adolphe de Rothschild portfolio CI
Frequently asked questions about injection of NMBA
What is injection of NMBA?
How does injection of NMBA work?
What is injection of NMBA used for?
Who makes injection of NMBA?
What drug class is injection of NMBA in?
What development phase is injection of NMBA in?
What are the side effects of injection of NMBA?
What does injection of NMBA target?
Related
- Drug class: All Neuromuscular blocking agent drugs
- Target: All drugs targeting Nicotinic acetylcholine receptor at neuromuscular junction
- Manufacturer: Fondation Ophtalmologique Adolphe de Rothschild — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation
- Compare: injection of NMBA vs similar drugs
- Pricing: injection of NMBA cost, discount & access